Hisamitsu Pharmaceutical : Notification of the commencement of the Phase II clinical study of HP-5070 in Japan (a transdermal drug for the treatment of primary local hyperhidrosis)
October 22, 2018 at 02:12 am EDT
Share
This material is an English translation of the press release announced on October 22, 2018 in Japanese, and the Japanese release is given priority about the content and the interpretation.
October 22, 2018
Notification of the commencement of the Phase II clinical study of HP-5070 in Japan (a transdermal drug for the treatment of primary local hyperhidrosis)
Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi) hereby announces that it has commenced of the Phase II clinical study for ''primary local hyperhidrosis'' in Japan (Development code: HP-5070, hereinafter referred to as "the product").
In the Phase II clinical study, the efficacy and safety of administration of the product will be compared with a placebo in patients with primary local hyperhidrosis.
In the future, we aim to initiate a Phase III clinical study during FY 2020.
Attachments
Original document
Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 22 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 22 October 2018 06:07:03 UTC
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
Hisamitsu Pharmaceutical : Notification of the commencement of the Phase II clinical study of HP-5070 in Japan (a transdermal drug for the treatment of primary local hyperhidrosis)
HISAMITSU PHARMACEUTICAL CO., INC. 
